{"id":"https://openalex.org/W2602895412","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.7050","title":"Rapid identification of drug-resistant BCR-ABL(+) leukemia.","display_name":"Rapid identification of drug-resistant BCR-ABL(+) leukemia.","publication_year":2013,"publication_date":"2013-05-20","ids":{"openalex":"https://openalex.org/W2602895412","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.7050","mag":"2602895412"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2013.31.15_suppl.7050","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.7050","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.15_suppl.7050","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Ronald J. Rieder","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126126","display_name":"BioSense (United States)","ror":"https://ror.org/02pf22978","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ronald J. Rieder","raw_affiliation_strings":["BioSense Technologies, Inc., Woburn, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioSense Technologies, Inc., Woburn, MA","institution_ids":["https://openalex.org/I4210126126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100987318","display_name":"Zhihui Zhao","orcid":"https://orcid.org/0000-0001-5114-1266","observed_orcids":["https://orcid.org/0000-0001-5114-1266"]},"institutions":[{"id":"https://openalex.org/I4210126126","display_name":"BioSense (United States)","ror":"https://ror.org/02pf22978","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zhihui Zhao","raw_affiliation_strings":["BioSense Technologies, Inc., Woburn, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioSense Technologies, Inc., Woburn, MA","institution_ids":["https://openalex.org/I4210126126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083579969","display_name":"Alex Chalmers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126126","display_name":"BioSense (United States)","ror":"https://ror.org/02pf22978","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alex Chalmers","raw_affiliation_strings":["BioSense Technologies, Inc., Woburn, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioSense Technologies, Inc., Woburn, MA","institution_ids":["https://openalex.org/I4210126126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071023119","display_name":"Richard Maury Stone","orcid":"https://orcid.org/0000-0002-7526-2633","observed_orcids":["https://orcid.org/0000-0002-7526-2633"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard M. Stone","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5051795460","display_name":"Ilene A Galinsky","orcid":"https://orcid.org/0000-0002-9158-5061","observed_orcids":["https://orcid.org/0000-0002-9158-5061"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ilene Galinski","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"31","issue":"15_suppl","first_page":"7050","last_page":"7050"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bcr-abl-positive-leukemia","display_name":"BCR-ABL-positive leukemia","score":0.9210000038146973},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9580000042915344},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.7870000004768372},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9729999899864197},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.9010000228881836},{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":0.9860000014305115},{"id":"https://openalex.org/keywords/nilotinib","display_name":"nilotinib","score":1.0},{"id":"https://openalex.org/keywords/ponatinib","display_name":"ponatinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/dielectric-constant","display_name":"dielectric constant","score":0.8790000081062317},{"id":"https://openalex.org/keywords/cellular-stress","display_name":"cellular stress","score":0.722000002861023},{"id":"https://openalex.org/keywords/t315i-mutation","display_name":"T315I mutation","score":0.7850000262260437},{"id":"https://openalex.org/keywords/peripheral-blood-mononuclear-cells","display_name":"peripheral blood mononuclear cells","score":0.7609999775886536},{"id":"https://openalex.org/keywords/rapid-drug-resistance-detection","display_name":"rapid drug resistance detection","score":0.5080000162124634}],"concepts":[{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.8223283886909485},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7752078771591187},{"id":"https://openalex.org/C2780381907","wikidata":"https://www.wikidata.org/wiki/Q198728","display_name":"Ponatinib","level":5,"score":0.7360342741012573},{"id":"https://openalex.org/C2778903051","wikidata":"https://www.wikidata.org/wiki/Q5630035","display_name":"HL60","level":3,"score":0.6820836067199707},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.656417191028595},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.6183621287345886},{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.5995978116989136},{"id":"https://openalex.org/C171122931","wikidata":"https://www.wikidata.org/wiki/Q6324626","display_name":"K562 cells","level":3,"score":0.5651969909667969},{"id":"https://openalex.org/C2776960273","wikidata":"https://www.wikidata.org/wiki/Q729735","display_name":"Chronic myelogenous leukemia","level":3,"score":0.5649218559265137},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.5510820746421814},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.49048110842704773},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.48635488748550415},{"id":"https://openalex.org/C137061746","wikidata":"https://www.wikidata.org/wiki/Q736033","display_name":"Peripheral blood mononuclear cell","level":3,"score":0.4850594103336334},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.4722330570220947},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.44442018866539},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.32194674015045166},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.25221961736679077},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.18904384970664978},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.11394217610359192},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.07349863648414612},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2013.31.15_suppl.7050","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.7050","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.15_suppl.7050","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","score":0.800000011920929,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2680356565","https://openalex.org/W2576920830","https://openalex.org/W2312202255","https://openalex.org/W2408896879","https://openalex.org/W2557234541","https://openalex.org/W2110561019","https://openalex.org/W2595159554","https://openalex.org/W2124107172","https://openalex.org/W2166342674","https://openalex.org/W2051960175"],"abstract_inverted_index":{"7050":[0],"Background:":[1],"Approximately":[2],"20%":[3],"of":[4,36,59,69,82,113,244,264,316],"patients":[5,12,148],"with":[6,13,43,166,229],"chronic":[7],"myeloid":[8],"leukemia":[9,16],"and":[10,71,89,98,103,180,221,258,285],"most":[11],"BCR-ABL-positive":[14],"acute":[15],"demonstrate":[17],"resistance":[18],"to":[19,74,94,105,130,152,198,215,247,255,268,274,280,288,290,321],"imatinib":[20,114],"mesylate":[21],"resulting":[22],"in":[23,39,110,134,150,195,224,307,319],"treatment":[24],"failure":[25],"or":[26,100,120],"suboptimal":[27],"patient":[28,266],"outcomes.":[29],"We":[30,137],"hypothesize":[31],"that":[32],"monitoring":[33,313],"the":[34,57,60,63,111,124,153,167,242,253,269,314],"development":[35,315],"cellular":[37,135,317],"stress":[38,318],"BCR-ABL":[40,90],"cells":[41,65,87,246,296,303],"incubated":[42,165],"tyrosine":[44],"kinase":[45],"inhibitors":[46],"(TKI)":[47],"can":[48,297],"be":[49,95,298],"used":[50],"as":[51],"an":[52],"early":[53],"marker":[54],"for":[55,187,211],"determining":[56],"effects":[58],"drugs":[61,203,323],"on":[62,142],"cancer":[64],"enabling":[66],"rapid":[67],"identification":[68],"drug-resistance":[70],"facilitating":[72],"change":[73,194],"more":[75],"effective":[76],"therapies.":[77],"Methods:":[78],"The":[79],"dielectric":[80,185],"permittivities":[81],"non-leukemic":[83],"peripheral":[84],"blood":[85,267],"mononuclear":[86],"(PBMCs)":[88],"cell":[91,190,212,231,282,305],"lines":[92,191,213,232],"known":[93],"resistant":[96,230],"(K562R":[97],"BaF3/T315I)":[99],"sensitive":[101,214,281],"(K562":[102],"HL60/BCR-ABL)":[104],"different":[106],"TKIs":[107,218,271],"were":[108,204,219,236,277],"measured":[109,272],"presence":[112],"(IMT),":[115],"dasatinib":[116],"(DAS),":[117],"nilotinib":[118],"(NIL),":[119],"ponatinib":[121],"(PON)":[122],"using":[123,324],"Z-Sense":[125],"differential":[126,325],"impedance":[127,326],"sensing":[128],"platform":[129],"record":[131],"any":[132],"changes":[133],"stress.":[136],"also":[138],"performed":[139],"similar":[140,197,279],"measurements":[141,284],"PBMCs":[143,158],"from":[144,252,301],"newly":[145],"diagnosed":[146],"CML":[147],"exposed":[149],"vitro":[151],"same":[154,217],"TKIs.":[155],"Results:":[156],"Non-leukemic":[157],"showed":[159,192],"no":[160,193,202],"significant":[161],"background":[162],"levels":[163],"when":[164],"following":[168],"TKI":[169,322],"concentrations:":[170],"IMT":[171,291],"(5":[172,175,182],"mg/mL),":[173,176,179],"DAS":[174],"NIL":[177],"(2.5":[178],"PON":[181,248],"ng/mL).":[183],"Normalized":[184],"responses":[186,209,254,263],"all":[188,208,262],"drug-resistant":[189,302],"value":[196,225],"control":[199],"runs":[200],"where":[201],"added.":[205],"In":[206],"contrast,":[207],"obtained":[210],"these":[216],"immediate":[220],"continuously":[222],"decreased":[223],"over":[226],"time":[227],"compared":[228],"(p<0.01).":[233],"All":[234],"sensitivities":[235],"confirmed":[237,287],"by":[238,312],"MTT":[239],"assay.":[240],"Notably,":[241],"response":[243,320],"BaF3/T315I":[245],"was":[249],"easily":[250],"distinguished":[251,300],"IMT,":[256],"DAS,":[257],"NIL.":[259],"Of":[260],"significance,":[261],"BCR-ABL(+)":[265,295],"four":[270],"prior":[273],"commencing":[275],"therapy":[276],"qualitatively":[278],"line":[283],"subsequently":[286],"respond":[289],"therapy.":[292],"Conclusions:":[293],"Drug-sensitive":[294],"readily":[299],"without":[304],"culturing":[306],"less":[308],"than":[309],"60":[310],"minutes":[311],"sensing.":[327]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2017-04-07T00:00:00"}